Citations 1
Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer’s disease: associations with β-amyloid-PET, neurodegeneration and cognition
Chatterjee, Pratishtha , Gordon, Brian A. , Boonkamp, Lynn , Armstrong, Nicola J. , Xiong, Chengjie , Li, Yan , Taddei, Kevin , Chhatwal, Jasmeer P. , Graff‐Radford, Neill R. , Farlow, Martin R. , Mori, Hiroshi , Perrin, Richard J. , Fagan, Anne M. , Gordon, Brian A , Vermunt, Lisa , Pedrini, Steve , Singh, Abhay Kumar , Sohrabi, Hamid R. , Molloy, Mark P. , Benzinger, Tammie L.S. , Morris, John C. , Karch, Celeste M. , Berman, Sarah , Day, Gregory S. , Fox, Nick C. , Goate, Alison , Hassenstab, Jason , Lee, Jae‐Hong , Xiong, Chengjie , McDade, Eric , Sánchez‐Valle, Raquel , Schofield, Peter R. , Jucker, Mathias , Masters, Colin L. , Bateman, Randall J. , Martins, Ralph N. , Teunissen, Charlotte E.
No container title available | June 29, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available
Abstract Glial fibrillary acidic protein (GFAP) is a promising candidate blood-based biomarker for Alzheimer’s disease (AD) diagnosis and prognostication. The timing of its disease-associated changes, its clinical correlates, and biofluid-type dependency will influence its clinical utility. We evaluated plasma, serum, and CSF GFAP in families with autosomal dominant AD (ADAD), leveraging the predictable age at symptom onset to determine changes by stage of disease. Plasma GFAP elevations appear a decade before expected symptom onset, after β-amyloid accumulation and prior to neurodegeneration and cognitive decline. Plasma GFAP distinguished β-amyloid-positive from β-amyloid-negative ADAD participants and showed a stronger relationship with β-amyloid load in asymptomatic than symptomatic ADAD. Higher plasma GFAP was associated with the degree and rate of neurodegeneration and cognitive impairment. Serum GFAP showed similar relationships, but these were less pronounced for CSF GFAP. Our findings support a role for plasma GFAP as a clinical biomarker for β-amyloid-associated cognitive deterioration in AD.